Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
September 25 2024 - 8:00AM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced an
abstract has been accepted for a poster presentation at the
American College of Rheumatology (ACR) Convergence 2024, which will
be held November 14-19, 2024 in Washington, DC.
The poster will highlight the preclinical data and key elements
of the clinical trial design that supported the investigational new
drug (IND) clearance to evaluate CB-010 in the GALLOP Phase 1
clinical trial in patients with lupus nephritis (LN) and extrarenal
lupus (ERL). Details of the poster presentation are as follows:
Title: Preclinical Analysis of CB-010, an
Allogeneic anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, for
the Treatment of Patients with Refractory Systemic Lupus
Erythematosus (SLE)Presenter: Elizabeth Garner,
PhD, executive director of T cell therapeutics and translational
sciences laboratory, Caribou BiosciencesDate and
time: Saturday, November 16, 2024, 10:30 am-12:30 pm
ESTSession: B cell biology & targets in
autoimmune & inflammatory disease
posterLocation: Walter E. Washington Convention
Center, Washington, DCAbstract number: 0018
2024 ACR Convergence abstracts will be published at
www.acrabstracts.org and the poster presentation will be available
on Caribou’s Scientific Publications webpage on Thursday, November
14, 2024 at 10:00 am EST.
About CB-010CB-010 is the lead clinical-stage
product candidate from Caribou’s allogeneic CAR-T cell therapy
platform, and it is being evaluated in patients with relapsed or
refractory B cell non-Hodgkin lymphoma (r/r B-NHL) in the ongoing
ANTLER Phase 1 clinical trial and will be evaluated in patients
with lupus nephritis (LN) and extrarenal lupus (ERL) in the GALLOP
Phase 1 clinical trial. To Caribou’s knowledge, CB-010 is the first
allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a
genome-editing strategy designed to improve CAR-T cell activity by
limiting premature CAR-T cell exhaustion. The FDA granted CB-010
Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug
designations for B-NHL and Fast Track designations for both B-NHL
and refractory systemic lupus erythematosus (SLE). Additional
information on the ANTLER trial (NCT04637763) can be found at
clinicaltrials.gov.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. The potential for
CRISPR systems to edit at unintended genomic sites, known as
off-target editing, may lead to harmful effects on cellular
function and phenotype. In response to this challenge, Caribou has
developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced
“chardonnays”) that direct substantially more precise genome
editing compared to all-RNA guides. Caribou is deploying the power
of its chRDNA technology to carry out high efficiency multiple
edits, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou
Biosciences is a clinical-stage CRISPR genome-editing
biopharmaceutical company dedicated to developing transformative
therapies for patients with devastating diseases. The company’s
genome-editing platform, including its Cas12a chRDNA technology,
enables superior precision to develop cell therapies that are
armored to potentially improve activity against disease. Caribou is
advancing a pipeline of off-the-shelf cell therapies from its CAR-T
platform as readily available treatments for patients with
hematologic malignancies and autoimmune diseases. Follow us
@CaribouBio and visit www.cariboubio.com.
Forward-looking statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. In some cases,
you can identify forward-looking statements by terms such as “may,”
“will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential,” or “continue,” or the negative
of these terms or other similar expressions, although not all
forward-looking statements contain these words. These
forward-looking statements include, without limitation, statements
related to Caribou’s strategy, plans, and objectives, and
expectations regarding its clinical development programs, including
its expectations relating to development, regulatory approval,
results, and the timing of and updates from its ANTLER Phase 1
clinical trial for CB-010, and its GALLOP Phase 1 clinical trial
for CB-010. Management believes that these forward-looking
statements are reasonable as and when made. However, such
forward-looking statements are subject to risks and uncertainties,
and actual results may differ materially from any future results
expressed or implied by the forward-looking statements. Risks and
uncertainties include, without limitation, risks inherent in the
development of cell therapy products; uncertainties related to the
initiation, cost, timing, progress, and results of Caribou’s
current and future research and development programs, preclinical
studies, and clinical trials; and the risk that initial,
preliminary, or interim clinical trial data will not ultimately be
predictive of the safety and efficacy of Caribou’s product
candidates or that clinical outcomes may differ as patient
enrollment continues and as more patient data becomes available;
the risk that preclinical study results observed will not be borne
out in human patients or different conclusions or considerations
are reached once additional data have been received and fully
evaluated; the ability to obtain key regulatory input and
approvals; as well as other risk factors described from time to
time in Caribou’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year
ended December 31, 2023 and subsequent filings. In light of the
significant uncertainties in these forward-looking statements, you
should not rely upon forward-looking statements as predictions of
future events. Except as required by law, Caribou undertakes no
obligation to update publicly any forward-looking statements for
any reason.
Caribou Biosciences, Inc.
contacts:Investors:Amy Figueroa,
CFAinvestor.relations@cariboubio.com
Media:Peggy Vorwald,
PhDmedia@cariboubio.com
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Oct 2024 to Nov 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Nov 2023 to Nov 2024